Psoriatic Arthritis malady

Genetics Home Reference: Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pitted or ridged, crumble, or separate from the nail beds.¹⁷

MalaCards: Psoriatic Arthritis, also known as psoriasis, is related to arthritis and juvenile rheumatoid arthritis. An important gene associated with Psoriatic Arthritis is LTA (lymphotoxin alpha (TNF superfamily, member 1)), and among its related pathways are Graft-versus-host disease and NF-kappaB Signaling. The drugs coal tar and betamethasone dipropionate and the compounds vitamin a and cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include heart, thyroid and skin, and related mouse phenotypes are respiratory system and renal/urinary system.

Disease Ontology: A syndrome that occurs in humans with psoriasis who also experience symptoms similar to arthritis.⁶

Wikipedia: Psoriatic arthritis (also arthritis psoriatica, arthropathic psoriasis or psoriatic arthropathy) is a...⁴⁴ more...

OMIM: 607507

Aliases & Descriptions:

psoriatic arthritis 6 17 8 33 psoriasis 17 43 arthropathic psoriasis 6 arthritis, psoriatic 43

arthritis psoriatica 6 arthritis psoriatic 32 arthritis 43

Diseases related to psoriatic arthritis by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1075)

id	Related Disease	Score	Top Affiliating Genes
1	arthritis	39.9	MMP3, FGF1, IL17A, IL1A, IL1B, IL6
2	juvenile rheumatoid arthritis	36.2	S100A8, S100A9, IL1A, IL1R1, IL1RAPL2, IL1RN
3	rheumatoid arthritis	36.0	CIITA, HLA-DRB1, PTPN22, SLC22A4
4	ankylosing spondylitis	33.3	CD79A, CD40LG, MMP3, IL17A, IL1R1, IL1RAPL2
5	guttate psoriasis	33.2	KIR2DS1, CDSN, HLA-C, TRB@, NOD2
6	septic arthritis	33.1	RELA, MMP2, MMP9, IL1B, IFNG, TNF
7	tuberculosis	32.1	IL10, IL12B, IL1B, IL1RN, IL4, CCL2
8	reactive arthritis	31.9	BPI, CD79A, HLA-B, TRH, CRP, COMP
9	blau syndrome	31.7	IL10, IL1B, IL1RAPL2, TNF, NOD2
10	asthma	31.5	IL12B, IL13, CCL11, TNF
11	adult-onset still's disease	31.3	IL18, IL1R1, IL1RAPL2, IL6, CRP
12	rheumatoid arthritis, association with	30.9	SELE, CIITA, MTHFR, CD79A, MMP9, FLG
13	spondylarthropathy	30.3	S100A8, S100A9, IL1RAPL2, TNF, CRP, TLR4
14	palindromic rheumatism	30.0	IL1B, HLA-DRB1, TNF, TNFRSF1A, TNFRSF1B, PTPN22
15	multiple sclerosis	29.9	CD58, MICB, MICA, IL1A, IL1B, IL1RN
16	spondyloarthropathy	29.8	KIR2DL1, KIR2DL3, KIR3DL1, KIR2DS2, KIR2DS1, KIR2DL2
17	periodontitis	29.8	MMP1, MMP3, MMP9, FCGR3A, IL10, IL17A
18	visceral leishmaniasis	29.7	IL10, IL4, IFNG, LTA
19	dermatitis herpetiformis	29.5	SELE, CD79A, CD40LG, MMP3, IL13, IL2RA
20	hepatitis	29.2	CD58, IFNA1, HLA-A, HLA-DRB1, TNFRSF1A, CXCL10
21	autoimmune thyroiditis	29.2	CIITA, CD58, CD59, IL12B, IL2RA, IL4
22	joint disorders	29.1	MMP3, IL1R1, IL1RAPL2, IL1RN, IL6, TNF
23	bullous pemphigoid	29.0	CIITA, CD79A, FLG, IL13, CCL11, CCL5
24	sapho syndrome	29.0	MDM2, HLA-B, TP53, TNF, NOD2, PRL
25	back pain	28.9	MMP3, MMP9, IL1A, IL1B, IL1RN, IL6
26	primary biliary cirrhosis	28.7	CIITA, CD58, CD79A, CD40LG, HLA-B, HLA-DRB1
27	amyloidosis	28.7	LPA, CD79A, CDSN, CD40LG, MMP3, MMP9
28	ischemic heart disease	28.5	LPA, FGF1, IL1RN, APOA1, TNFRSF1A, CRP
29	gout	28.5	SELE, LPA, LPXN, MTHFR, S100A9, CD79A
30	synovitis	28.2	SELE, VEGFA, VCAM1, S100A8, S100A9, MRAP
31	polymyalgia rheumatica	28.2	VEGFA, MMP3, IL12B, IL1A, IL1B, IL1R1
32	interstitial lung disease	28.1	IL1A, IL1R1, IL1RAPL2, IL1RN, IL8, ANXA1
33	contact dermatitis	28.1	SELE, VCAM1, LCE3B, LCE3C, FLG, IL10
34	mixed connective tissue disease	28.0	S100A8, S100A9, CD40LG, MICA, IL6, APOH
35	leprosy	28.0	IL10, HLA-DQA1, HLA-DRB1, LTA, TLR2
36	t-cell leukemia	27.9	RELA, IL1A, IL2, IL2RA, CCR4, ICAM1
37	thrombocytosis	27.7	VEGFA, MTHFR, CD79A, CD40LG, IL1A, IL1B
38	spondylitis	27.7	RELA, KIR2DL1, KIR2DL3, KIR3DL1, KIR2DS2, KIR2DS1
39	hypoglycemia	27.7	VEGFA, CIITA, CD79A, FGF2, IL1B, IL6
40	erythema multiforme	27.6	CD79A, CCL22, CCL2, CCL5, ICAM1, TNF
41	schizophrenia	27.5	MTHFR, MICB, IL1B, IL1RN, IL2, IL4
42	celiac disease	27.3	CIITA, IL6, HLA-DQA1, HLA-DRB1, TNF, SPINK5
43	lyme disease	27.3	CIITA, CD40LG, MMP9, IL17A, IL1B, IL23R
44	lymphopenia	27.2	CIITA, CD59, IL10, IL15, IL18, IL1RN
45	crohn's disease	27.2	BPI, IL10, IL12B, IL13, IL17A, IL18
46	scleritis	27.2	MMP9, IL1RAPL2, IL4, CCL2, IFNG, HLA-B
47	pyoderma gangrenosum	27.1	CD40LG, MMP1, IL1R1, IL6, IL8, APOH
48	pyoderma	27.1	CD40LG, MMP1, IL1R1, IL6, IL8, APOH
49	castleman's disease	27.0	VEGFA, IL10, IL6, CCL4, IFNA1, TP53
50	rheumatoid vasculitis	27.0	SELE, VCAM1, IL1RAPL2, ICAM1, HLA-DRB1, TNF

Clinical features from OMIM: 607507

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 acitretin, alefacept, aloe vera, anthralin, anthralin pwdr [va product], auranofin, aurothioglucose, betamethasone, betamethasone acetate, betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, betamethasone valerate, betamethasone valerate pwdr [va product], calcipotriene, calcitriol, cholecalciferol, coal tar, coal tar distillate, coal tar distillate [va product], coal tar extract, coal tar,colloidal, coal tar,crude, coal tar,refined, cod liver oil [va product], devils claw, etanercept, etretinate, fish liver oil, fluocinolone, fluocinolone acetonide, hydroxyurea, meclofenamate, meclofenamate sodium, methotrexate, methotrexate sodium, methoxsalen, mycophenolate mofetil, mycophenolate mofetil hydrochloride, mycophenolic acid, salicylic acid, salicylic acid pwdr [va product], salsalate, sulfur, sulfur pwdr [va product], sulfur,colloidal, sulfur,precipitated, tazarotene, thioguanine, trioxsalen

MalaCards organs/tissues related to psoriatic arthritis:

²²

MGI Mouse Phenotypes related to psoriatic arthritis:

²⁵ (show all 23)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.7	PTPN22, TRAF3IP2, CCR4, CCR2, IL12B, JAM3
2	renal/urinary system phenotype	MP:0005367	10.2	GAPDH, SLC22A5, SOD2, NGFR, TNIP1, TNFRSF1B
3	endocrine/exocrine gland phenotype	MP:0005379	10.0	TLR2, LTA, PHB2, CTLA4, TNIP1, TRH
4	hematopoietic system phenotype	MP:0005397	9.2	CCR2, CCR4, CCL11, ERAP1, HLA-C, HLA-DQA1
5	no phenotypic analysis	MP:0003012	8.3	ERAP1, HLA-C, TP53, TNFSF12, TNIP1, CYP1A1
6	immune system phenotype	MP:0005387	8.3	CIITA, ERAP1, HLA-C, HLA-DQA1, TRAF3IP2, TRB@
7	normal phenotype	MP:0002873	8.3	IL4, CCL11, IFNG, TRB@, CYP1A1, CTLA4
8	digestive/alimentary phenotype	MP:0005381	8.2	VEGFA, JAM3, ITGB7, MMP9, IL12B, IL17A
9	reproductive system phenotype	MP:0005389	8.1	IFNG, TNF, TNFRSF1A, TNFSF11, PHB2, TLR4
10	liver/biliary system phenotype	MP:0005370	8.0	IFNG, TRB@, TP53, TNIP1, PTPN22, CTLA4
11	nervous system phenotype	MP:0003631	8.0	COL1A1, NGF, LTA, ABCC1, TLR2, TLR4
12	adipose tissue phenotype	MP:0005375	7.9	PPARG, RPTOR, COL1A1, ACE, TLR2, TLR4
13	skeleton phenotype	MP:0005390	7.7	TNFSF11, CTLA4, PPARG, NOD2, RPTOR, COMP
14	integument phenotype	MP:0010771	7.3	RELA, CDSN, FLG, IL13, IL1R1, IL36RN
15	muscle phenotype	MP:0005369	7.0	PPARG, TNFRSF1B, TNFRSF1A, TNF, TP53, RPTOR
16	growth/size phenotype	MP:0005378	6.8	RELA, SELE, VCAM1, USP8, MTHFR, CDSN
17	tumorigenesis	MP:0002006	6.6	JAM3, CDSN, MMP2, ICAM1, TRB@, TP53
18	vision/eye phenotype	MP:0005391	5.9	PPARG, TNFRSF1B, TNFRSF1A, TNF, TP53, ICAM1
19	mortality/aging	MP:0010768	5.8	IL4R, TNIP1, PTPN22, SPINK5, CTLA4, PPARG
20	cardiovascular system phenotype	MP:0005385	5.5	MMP15, APOA1, ANGPT2, ANXA1, CCR2, CCL2
21	behavior/neurological phenotype	MP:0005386	5.1	NGF, PHB2, COMP, COL1A1, RPTOR, PPARG
22	homeostasis/metabolism phenotype	MP:0005376	4.9	TLR2, TLR4, TLR9, PRL, SOD2, SLC17A5
23	cellular phenotype	MP:0005384	4.4	PPARG, SLC17A5, SOD2, CXCL13, NOD2, RPTOR

Articles related to psoriatic arthritis:

(show top 50)    (show all 230)

id	Title	Authors	Year	Affiliating Genes
1	Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels. (21190865)	Xia L.... Lu J.	2011	MMP3, CCL2, IL15
2	Golimumab: A novel anti-TNF-alpha human monoclonal an tibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis . (20200692)	Campas-Moya C.	2010	TNF
3	Hepatoprotective effect of tumour necrosis factor alp ha blockade in psoriatic arthritis: a cross-sectional study. (19854710)	Seitz M.... Dufour J.F.	2010	TNF
4	Genetic variation at the CCR5/CCR2 gene cluster and r isk of psoriasis and psoriatic arthritis. (20153665)	Soto-SA!nchez J.... Alvarez V.	2010	CCR5, CCR2
5	Expression of MDC/CCL22 and its receptor CCR4 in rheu matoid arthritis, psoriatic arthritis and osteoarthritis. (19942450)	Flytlie H.A.... Deleuran B.	2010	CCR4, CCL22
6	Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. (19327233)	Oliviero F.... Punzi L.	2009	APOA1, LPA
7	Lack of association between angiotensin I-converting enzyme insertion/deletion polymorphism and psoriasis or psoriatic arthritis in Spain. (19930490)	Coto-Segura P.... Santos-Juanes J.	2009	ACE
8	Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis. (18752933)	Shibata S.... Tamaki K.	2009	IL23A
9	The effectiveness of a traditional therapeutical appr oach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. (18030515)	Scarpa R.... Del Puente A.	2008	CRP
10	A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. (17827183)	Ravindran V.... Choy E.H.	2008	TNF
11	Loss-of-function variants of the filaggrin gene are not major susceptibility factors for psoriasis vulgaris or psoriatic arthritis in German patients. (17255953)	Huffmeier U.... Reis A.	2007	FLG
12	Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. (17911474)	Cordiali-Fei P.... Ensoli F.	2007	TNF, SELE
13	Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. (17911480)	Amital H.... Rubinow A.	2007	TNF, IL6, IL1RAPL2
14	Polymorphism of the prolactin extrapituitary promoter in psoriatic arthritis. (17564716)	Stolfa J.... Dostal C.	2007	PRL
15	Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. (17179176)	GratacA^s J.... Torre-Alonso J.C.	2007	CRP
16	PPAR-gamma gene polymorphisms and psoriatic arthritis. (16783862)	Butt C.... Rahman P.	2006	PPARG
17	Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. (16574701)	Hofbauer L.C.... Lange U.	2006	TNFRSF11B
18	A distinct inflammatory gene expression profile in patients with psoriatic arthritis. (16971957)	Stoeckman A.K.... Peterson E.J.	2006	ZNF395
19	Association between the interleukin-1 family gene cluster and psoriatic arthritis. (16918024)	Rahman P.... Gladman D.	2006	IL1B, IL1A, IL36RN
20	CARD15 mutations in patients with plaque-type psoriasis and psoriatic arthritis: lack of association. (16402184)	Jenisch S.... Weichenthal M.	2006	NOD2
21	Cytokine profiles during infliximab monotherapy in psoriatic arthritis. (16120138)	Mastroianni A.... Berardesca E.	2005	MMP2, IL6, VEGFA
22	Treatment advances in psoriatic arthritis. (16045835)	Ruderman E.M.	2005	TNF
23	Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. (16265699)	Delaunay C.... Claudepierre P.	2005	TNF
24	Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. (16112031)	Williams F.... Middleton D.	2005	KIR3DL1, KIR2DL1, KIR2DL3
25	Lack of genetic association of the three more common polymorphisms of CARD15 with psoriatic arthritis and psoriasis in a German cohort. (15539411)	Lascorz J.... Reis A.	2005	HLA-C, NOD2, CCHCR1
26	Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective. (15251081)	Kane D.... FitzGerald O.	2004	TNF
27	The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritis. (15513680)	Queiro-Silva R.... Lopez-Lagunas I.	2004	HLA-DRB4
28	Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. (15194570)	Goedkoop A.Y.... Tak P.P.	2004	TNF
29	Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, vasculitis and SjAPgren's syndrome. (15059267)	Skoumal M.... Dunky A.	2004	COMP
30	Manganese superoxide dismutase gene polymorphisms in psoriatic arthritis. (15266664)	Yen J.H.... Liu H.W.	2003-2004	SOD2
31	Current concepts and new developments in the treatment of psoriatic arthritis. (12810935)	Pipitone N.... Pitzalis C.	2003	TNF
32	Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. (14678719)	Victor F.C.... Menter A.	2003	TNF
33	Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. (12832707)	Foell D.... Roth J.	2003	S100A12
34	A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. (12474146)	Karason A.... Gulcher J.R.	2003	NOD2
35	Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient care. (11990862)	Ruderman E.M.	2002	TNF
36	Clinical features of psoriatic arthritis. (11990861)	Krueger G.G.	2002	TNF
37	Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. (12011375)	Al-Heresh A.M.... McHugh N.	2002	TNF, TNFRSF1B, IL10
38	Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. (12426660)	Cauza E.... Wagner E.	2002	TNF
39	Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis. (11796407)	Spadaro A.... Taccari E.	2002	IL13
40	Successful rechallenge with anti-tumor necrosis facto r alpha for psoriatic arthritis after development of demyelinating nervous syst em disease during initial treatment: comment on the article by Mohan et al. (12428265)	Cisternas M.... Jacobelli S.	2002	TNF
41	Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. (12635469)	Cauza E.... Kostner K.	2002	TNF
42	Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. (12384938)	Kraan M.C.... Tak P.P.	2002	CD58
43	Renal abnormalities in a population of patients with psoriatic arthritis. (11727841)	Alenius G.M.... Dahlqvist S.R.	2001	CRP
44	Matrix metalloproteinase 9 (MMP-9) in patients with psoriatic arthritis and rheumatoid arthritis. (11791658)	Alenius G.M.... RantapAoAo Dahlqvist S.	2001	MMP9
45	Lack of association between promoter polymorphism of the tumor necrosis factor-alpha gene and psoriatic arthritis in Japanese patients. (11121160)	Hamamoto Y.... Muto M.	2000	TNF
46	The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. (10323458)	Gonzalez S.... Lopez-Larrea C.	1999	MICA
47	Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis. (9793799)	Biasi D.... Bambara L.M.	1998	IL8
48	Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. (8546722)	Pitzalis C.... Panayi G.S.	1996	SELE
49	Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. (7538776)	Veale D.... FitzGerald O.	1995	ICAM1, SELE, VCAM1
50	Increased serum level of interleukin-6 in patients with psoriatic arthritis and thrombocytosis. (8586748)	Yasumoto S.... Hori Y.	1995	IL6

Genes related to psoriatic arthritis according to GeneCards:

(show top 50)    (show all 156)

id	Symbol	Description	Score	GeneCards Section Context
1	LTA	lymphotoxin alpha (TNF superfamily, member 1)	11.1	Publications, Summaries
2	TNIP1	TNFAIP3 interacting protein 1	11.1	Publications, Summaries
3	NOD2	nucleotide-binding oligomerization domain containing 2	11.0	Publications
4	MIR146A	microRNA 146a	11.0	Publications
5	IRAK1	interleukin-1 receptor-associated kinase 1	11.0	Publications
6	TNF	tumor necrosis factor	11.0	Publications
7	IL1B	interleukin 1, beta	11.0	Publications
8	IL1RN	interleukin 1 receptor antagonist	11.0	Publications
9	IL1RAPL2	interleukin 1 receptor accessory protein-like 2	11.0	Publications
10	IL10	interleukin 10	11.0	Publications
11	IL6	interleukin 6 (interferon, beta 2)	11.0	Publications
12	PSORS4	psoriasis susceptibility 4	11.0	Publications
13	PSORS5	psoriasis susceptibility 5	11.0	Publications
14	PSORS2	psoriasis susceptibility 2	11.0	Publications
15	LCE3B	late cornified envelope 3B	11.0	Publications
16	LCE3C	late cornified envelope 3C	11.0	Publications
17	NAT9	N-acetyltransferase 9 (GCN5-related, putative)	11.0	Publications
18	IGHA1	immunoglobulin heavy constant alpha 1	11.0	Publications
19	CDSN	corneodesmosin	11.0	Publications
20	KIR2DS1	killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1	11.0	Publications
21	TNFRSF12A	tumor necrosis factor receptor superfamily, member 12A	11.0	Publications
22	HCP5	HLA complex P5 (non-protein coding)	11.0	Publications
23	S100A12	S100 calcium binding protein A12	11.0	Publications
24	KIR2DS2	killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2	11.0	Publications
25	TRAF3IP2	TRAF3 interacting protein 2	11.0	Publications
26	CCHCR1	coiled-coil alpha-helical rod protein 1	11.0	Publications
27	PSORS1C1	psoriasis susceptibility 1 candidate 1	11.0	Publications
28	IL36RN	interleukin 36 receptor antagonist	11.0	Publications
29	TNFSF12	tumor necrosis factor (ligand) superfamily, member 12	11.0	Publications
30	IL23A	interleukin 23, alpha subunit p19	11.0	Publications
31	FBXL19	F-box and leucine-rich repeat protein 19	11.0
32	HLA-C	major histocompatibility complex, class I, C	11.0	Publications
33	MRAP	melanocortin 2 receptor accessory protein	11.0
34	CCL27	chemokine (C-C motif) ligand 27	11.0	Publications
35	MMP15	matrix metallopeptidase 15 (membrane-inserted)	11.0	Publications
36	KIR2DL2	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	11.0	Publications
37	NDUFA5	NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13kDa	11.0
38	MICA	MHC class I polypeptide-related sequence A	11.0	Publications
39	COMP	cartilage oligomeric matrix protein	11.0	Publications
40	TNFAIP8L3	tumor necrosis factor, alpha-induced protein 8-like 3	11.0
41	ZNF395	zinc finger protein 395	11.0	Publications
42	IL17D	interleukin 17D	11.0	Publications
43	RNF114	ring finger protein 114	11.0
44	ITGB7	integrin, beta 7	11.0	Publications
45	SLC9A3R1	solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 regulator 1	11.0	Publications
46	MICB	MHC class I polypeptide-related sequence B	11.0	Publications
47	SPPL2A	signal peptide peptidase like 2A	11.0	Publications
48	CCR4	chemokine (C-C motif) receptor 4	11.0	Publications
49	HLA-DRB4	major histocompatibility complex, class II, DR beta 4	11.0	Publications
50	CCL22	chemokine (C-C motif) ligand 22	11.0	Publications

Pathways related to psoriatic arthritis according to GeneDecks:

(show top 50)    (show all 184)

id	Pathway	Score	Top Affiliating Genes
1	Graft-versus-host disease20	10.2	KIR2DL1, KIR2DL3, KIR3DL1, KIR2DL2, IL1A, IL2
2	NF-kappaB Signaling3	10.2	RELA, IRAK1, IL1B, TNF, TNFRSF12A, TNFRSF1A
3	Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway10	10.0	RELA, CD40LG, IRAK1, TNF, TNFRSF12A, TNFRSF1A
4	Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway41	10.0	RELA, CD40LG, IRAK1, TNF, TNFRSF12A, TNFRSF1A
5	RAR-Gamma-RXR-Alpha Degradation36	9.9	IL15, IL2, IL23A, CCL4, CCL27, CCL22
6	African trypanosomiasis20	9.8	SELE, VCAM1, IL10, IL12B, IL18, IL1B
7	Immune System38	9.8	KIR2DL1, KIR2DL3, KIR3DL1, KIR2DS2, KIR2DS1, KIR2DL2
8	NFAT Signaling and Lymphocyte Interactions36	9.6	IL12B, IL13, IL15, IL1A, IL2, IL23A
9	Type I diabetes mellitus20	9.6	IL12B, IL1A, IL1B, IL2, IFNG, HLA-A
10	Regulation of eIF4 and p70S6K36	9.6	ITGB7, FGF1, IL12B, IL13, IL15, IL18
11	Leishmaniasis20	9.6	RELA, IRAK1, FCGR3A, IL10, IL12B, IL1A
12	Toxoplasmosis20	9.5	RELA, CIITA, CD40LG, IRAK1, IL10, IL12B
13	Endothelin-1 Signaling Pathway36	9.5	IL10, IL12B, IL13, IL18, IL1A, IL1B
14	IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types37	9.4	IL12B, IL17A, IL1B, IL23A, IL23R, IL4
15	THC Differentiation Pathway36	9.4	IL10, IL12B, IL18, IL2, IL2RA, IL4
16	Akt Signaling36	9.3	FGF1, IL10, IL12B, IL15, IL18, IL2
17	Cytokine production by Th17 cells in CF (Mouse model)41	9.3	RELA, IL12B, IL17A, IL23A, IL23R, IL6
18	Chemokine signaling pathway20	9.1	RELA, IL8, CCL4, CCR2, CCL27, CCL22
19	Cytokine production by Th17 cells in CF41	9.0	RELA, IL12B, IL17A, IL23A, IL23R, IL6
20	PGC1Alpha Pathway36	9.0	IL12B, IL13, IL15, IL18, IL1A, IL1B
21	NF-KappaB (p50-p65) Pathway36	8.9	RELA, IRAK1, FGF1, FGF2, IL1A, IL1B
22	NF-KappaB Family Pathway36	8.9	RELA, IRAK1, FGF1, FGF2, IL1A, IL1B
23	JNK Pathway36	8.9	FGF1, FGF2, IL1R1, IL2, IL2RA, IL4R
24	Toll-like receptor signaling pathway20	8.8	RELA, IRAK1, IL12B, IL1B, IL6, IL8
25	Tuberculosis20	8.8	RELA, CIITA, IRAK1, FCGR3A, IL10, IL12B
26	all-trans-Retinoic Acid Signaling in Brain36	8.8	IL10, IL12B, IL13, IL15, IL18, IL1A
27	Malaria20	8.7	SELE, VCAM1, CD40LG, IL10, IL18, IL1B
28	Transendothelial Migration of Leukocytes36	8.7	VCAM1, JAM3, ITGB7, MMP1, MMP2, MMP3
29	ERK Signaling36	8.6	ITGB7, IL10, IL12B, IL13, IL18, IL1A
30	Glucocorticoid Receptor Signaling36	8.5	IL10, IL12B, IL13, IL15, IL18, IL1A
31	SOCS Pathway36	8.5	FGF1, FGF2, IL10, IL12B, IL13, IL15
32	Molecular Mechanisms of Cancer36	8.5	ITGB7, FGF1, FGF2, IL12B, IL13, IL15
33	Chagas disease (American trypanosomiasis)20	8.4	RELA, IRAK1, IL10, IL12B, IL1B, IL2
34	PAK Pathway36	8.3	FGF1, FGF2, IL10, IL12B, IL13, IL15
35	Cytokine Network36	8.3	IL10, IL12B, IL13, IL15, IL18, IL1A
36	MIF Mediated Glucocorticoid Regulation36	8.3	IL10, IL12B, IL13, IL15, IL18, IL1A
37	MIF Regulation of Innate Immune Cells36	8.3	IL10, IL12B, IL13, IL15, IL18, IL1A
38	STAT3 Pathway36	8.2	IL10, IL12B, IL13, IL15, IL18, IL1A
39	Rho Family GTPases36	8.1	ITGB7, FGF1, FGF2, IL10, IL12B, IL13
40	PEDF Induced Signaling36	8.1	RELA, IL10, IL12B, IL13, IL15, IL18
41	TGF-Beta Pathway36	8.0	FGF1, FGF2, IL10, IL12B, IL13, IL15
42	Measles20	8.0	RELA, IRAK1, IL12B, IL13, IL1A, IL1B
43	MAPK Family Pathway36	7.8	FGF1, FGF2, IL10, IL12B, IL13, IL15
44	Tec Kinases Signaling36	7.8	ITGB7, IRAK1, FGF1, FGF2, IL10, IL13
45	Influenza A20	7.7	RELA, CIITA, IL12B, IL18, IL1A, IL1B
46	Rheumatoid arthritis20	7.6	VEGFA, MMP1, MMP3, IL15, IL17A, IL18
47	Antioxidant Action of Vitamin-C36	7.2	FGF1, FGF2, IL10, IL12B, IL13, IL15
48	p38 Signaling36	6.8	IRAK1, FGF1, FGF2, IL10, IL12B, IL13
49	JAK-STAT Pathway36	6.4	FGF1, FGF2, IL10, IL12B, IL13, IL15
50	Cytokine-cytokine receptor interaction20	5.6	VEGFA, CD40LG, IL10, IL12B, IL13, IL15

Compounds related to psoriatic arthritis according to GeneDecks:

(show top 50)    (show all 424)

id	Compound	Score	Top Affiliating Genes
1	vitamin a32 9 18 9	13.9	CRP
2	cyclophosphamide32 34 9 9	13.7	APOH, TRB@
3	nicotine32 34 9 9	13.4	FLG, ANXA1, SLC22A4, SLC17A5, SLC22A5
4	pravastatin32 34 9 18 9	14.4	SELE, LPA, IL18, IL6, APOA1, CCL2
5	adalimumab32 9 9	11.9	CD79A, MMP3, FCGR3A, IL10, IL1R1, IL1RAPL2
6	progesterone32 42 9 18 9	13.8	MMP15, ANXA1, CCL4, TRH, NGFR, EGF
7	peptidoglycan32	9.8	CIITA, IRAK1, IL10, IL12B, IL15, IL1B
8	methylcellulose32	9.8	CD59, FGF2, IL15, IL1A, IL4, IL6
9	toxin-132	9.6	CIITA, IL10, IL1B, IL1RN, IL2, IL8
10	lipoteichoic acid32	9.6	SELE, BPI, IRAK1, IL10, IL12B, IL18
11	prostaglandin32	9.5	MMP1, MMP3, MMP9, IL17A, IL1A, IL1B
12	leukotriene b432 42 18	11.5	MMP9, IL13, IL1A, IL1B, IL1R1, IL1RAPL2
13	h2o232	9.4	LPA, S100A9, CD79A, IL13, IL18, IL1RAPL2
14	sulfasalazine32 9 9	11.4	SELE, MTHFR, CD79A, CD40LG, MMP3, IL12B
15	8-isoprostane32	9.3	SELE, VCAM1, MMP2, MMP9, IL10, IL6
16	epinephrine32 9 18 9	12.3	SELE, CD79A, MMP1, MMP2, MMP9, IL1A
17	fenofibrate32 9 9	11.3	SELE, LPA, VCAM1, CD40LG, MMP9, IL6
18	mip 1alpha32	9.2	IL10, IL13, IL1B, IL4, IL6, IL8
19	rosiglitazone32 9 18 9	12.1	SELE, LPA, VCAM1, MMP1, MMP2, MMP9
20	etanercept32 9 9	11.0	MMP1, MMP3, FCGR3A, IL10, IL15, IL17A
21	tgf beta132	9.0	VCAM1, MMP1, MMP2, MMP3, MMP9, FGF1
22	estrogen32	8.7	LPA, MTHFR, MMP1, MMP2, MMP3, FGF1
23	imiquimod32 42 9 9	11.7	IL10, IL12B, IL18, IL1A, IL1RAPL2, IL6
24	n acetylcysteine32	8.7	SELE, VCAM1, CD79A, MMP1, MMP2, MMP3
25	rapamycin32 42	9.7	VEGFA, IL1R1, IL2, MDM2, CCR5, IFNG
26	chloroquine32 34 9 9	11.5	CIITA, CD79A, IL10, IL15, IL18, IL1R1
27	infliximab32 9 9	10.4	SELE, VEGFA, MMP1, MMP3, FLG, FGF2
28	superoxide32 18	9.3	LPA, VCAM1, S100A8, CD59, IL15, IL1B
29	cytochalasin d32 42	9.3	SELE, VCAM1, MMP1, MMP2, MMP3, MMP9
30	tarc32	8.2	IL10, IL13, IL18, IL1A, IL4, IL4R
31	poly(i-c)32	8.1	VCAM1, IL12B, IL15, IL18, IL1B, IL4
32	aspirin32 34 18	10.0	SELE, LPA, MTHFR, CD79A, CD59, CD40LG
33	atorvastatin32 34 9 18 9	12.0	SELE, VEGFA, LPA, VCAM1, CD59, CD40LG
34	hydrocortisone32 9 9	9.9	MMP1, MMP2, FGF1, FGF2, IL10, IL13
35	gm-csf32	7.9	VEGFA, IL10, IL13, IL15, IL18, IL1A
36	thalidomide32 42 9 9	10.9	VEGFA, CD40LG, FGF2, IL10, IL18, IL1B
37	methotrexate32 34 42 9 9	11.7	SELE, MTHFR, S100A8, S100A9, CD79A, MMP1
38	ly29400232	7.7	SELE, VEGFA, MMP2, MMP9, FGF2, IL10
39	il-1232	7.7	CD40LG, IL10, IL12B, IL13, IL15, IL18
40	pd 98,05932	7.6	VCAM1, MMP1, MMP2, MMP3, MMP9, FGF2
41	lipid32	7.4	KIR2DL1, KIR3DL1, SELE, LPA, LPXN, VCAM1
42	sb 20358032 42	8.4	SELE, VEGFA, VCAM1, MMP1, MMP2, MMP3
43	lactate32	7.4	SELE, VCAM1, BPI, CD79A, CD59, CD40LG
44	cholesterol32 9 18 9	10.2	SELE, LPA, LPXN, VCAM1, BPI, CIITA
45	indomethacin32 9 9	9.2	CD79A, CD40LG, MMP1, MMP3, IL13, IL17A
46	herbimycin a32 42	8.0	SELE, VCAM1, CD40LG, MMP1, MMP2, MMP9
47	simvastatin32 34 42 9 18 9	12.0	SELE, VEGFA, LPA, VCAM1, CIITA, MMP3
48	alanine32	5.9	RFC1, SELE, VCAM1, BPI, CIITA, CHRNA7
49	retinoic acid32 42 18	6.6	VCAM1, BPI, MTHFR, S100A8, S100A9, CD58
50	actinomycin d32	4.0	SELE, VEGFA, LPA, BPI, CIITA, CD40LG

Cellular components related to psoriatic arthritis according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	MHC class I protein complex	GO:042612	10.4	MICB, MICA, HLA-A, HLA-B, HLA-C
2	integral to lumenal side of endoplasmic reticulum membrane	GO:071556	10.3	SPPL2A, HLA-DRB4, HLA-DRB1, HLA-DQA1, HLA-C, HLA-B
3	ER to Golgi transport vesicle membrane	GO:012507	9.9	HLA-DRB4, HLA-DRB1, HLA-DQA1, HLA-C, HLA-B, HLA-A
4	cell surface	GO:009986	9.3	TNF, TNFRSF12A, TNFRSF1A, NOD2, NGFR, TLR2
5	integral to plasma membrane	GO:005887	8.8	TNFRSF1A, TNF, HLA-DRB4, HLA-DRB1, HLA-DQA1, HLA-C
6	external side of plasma membrane	GO:009897	8.2	IL17A, IL4, CCR4, CCR5, IFNG, ICAM1
7	plasma membrane	GO:005886	7.5	TNFRSF1A, TNFRSF12A, TNF, TRH, HLA-DRB4, HLA-DRB1
8	extracellular region	GO:005576	5.8	MMP9, CCL27, CCL22, CCL2, CCL11, CCL3
9	extracellular space	GO:005615	5.1	SELE, IL17D, IL18, IL1A, IL1B, IL1RN

Biological processes related to psoriatic arthritis according to GeneDecks:

(show top 50)    (show all 110)

id	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of granulocyte macrophage colony-stimulating factor production	GO:032725	10.7	IL23R, IL18, IL12B, IL23A, IL1B
2	positive regulation of NF-kappaB import into nucleus	GO:042346	10.7	IL1B, TLR9, IL12B, IL23A, TNF, TLR2
3	positive regulation of natural killer cell proliferation	GO:032819	10.7	IL15, IL18, IL23A, IL12B, IL23R
4	positive regulation of interleukin-6 production	GO:032755	10.6	TLR2, TNF, TLR9, TLR4, NOD2, IL6
5	positive regulation of interleukin-17 production	GO:032740	10.6	IL2, IL23A, NOD2, IL15, IL12B, IL18
6	positive regulation of I-kappaB kinase/NF-kappaB cascade	GO:043123	10.6	TLR9, TLR4, TNF, TRAF3IP2, CCL21, IL1B
7	positive regulation of interferon-gamma production	GO:032729	10.5	IL12B, IL18, IL1B, IL2, IL23A, TNF
8	chronic inflammatory response	GO:002544	10.5	CXCL13, CCL5, CCL11, VCAM1, S100A8, S100A9
9	negative regulation of interleukin-6 production	GO:032715	10.5	TLR9, TLR4, TNFRSF1A, TNF, IL10, BPI
10	positive regulation of interleukin-10 production	GO:032733	10.5	NOD2, IL12B, IL4, TLR9, CD40LG, TLR4
11	positive regulation of tissue remodeling	GO:034105	10.5	IL12B, IL15, IL18, IL2, IL23A
12	positive regulation of chemokine production	GO:032722	10.5	IL6, TNF, TLR2, TLR4, TLR9, IL18
13	negative regulation of growth of symbiont in host	GO:044130	10.4	IFNG, IL12B, IL10, LTA, TLR2, TNF
14	positive regulation of osteoclast differentiation	GO:045672	10.4	IL17A, IL23A, IL23R, IL12B, IFNG, TNF
15	regulation of immune response	GO:050776	10.3	FCGR3A, KIR2DL1, KIR2DL3, KIR3DL1, KIR2DS2, SPPL2A
16	positive regulation of activated T cell proliferation	GO:042104	10.3	IL23A, IL18, IL23R, IL2, IL4, IL12B
17	positive regulation of T cell proliferation	GO:042102	10.3	IL23R, IL1B, IL4, IL6, CCL5, IFNG
18	positive regulation of inflammatory response	GO:050729	10.3	TLR9, TLR4, TLR2, TNIP1, TNFRSF1A, CCL3
19	T-helper 1 type immune response	GO:042088	10.3	TLR4, IL12B, IL18, HLA-DRB1, HLA-DRB4
20	lipopolysaccharide-mediated signaling pathway	GO:031663	10.2	IL1B, CCL2, CCL3, IL18, CCL5, TNF
21	positive regulation of nitric-oxide synthase biosynthetic process	GO:051770	10.2	TLR2, TLR9, TLR4, NOD2, CCL2
22	defense response to bacterium	GO:042742	10.2	S100A12, BPI, TLR4, NOD2, MICA, IL10
23	positive regulation of interleukin-12 production	GO:032735	10.2	CD40LG, IL12B, IL23A, IL23R, IFNG, TLR2
24	positive regulation of MHC class II biosynthetic process	GO:045348	10.1	CIITA, TLR4, CD40LG, IL10, IL4, IFNG
25	cell-cell signaling	GO:007267	10.1	CCL4, IL2, IL1B, IL18, IL17A, IL15
26	positive regulation of tumor necrosis factor production	GO:032760	10.1	TLR2, NOD2, IFNG, CCL3, IL23A, IL18
27	response to lipopolysaccharide	GO:032496	10.1	S100A8, IRAK1, CXCL10, SELE, S100A9, MMP9
28	cellular response to organic cyclic compound	GO:071407	10.1	TNF, CCL5, CCL3, CCL2, IL1B, IL18
29	positive regulation of NF-kappaB transcription factor activity	GO:051092	10.1	TLR4, IRAK1, TLR9, NFKBIA, NFKB1, NOD2
30	positive regulation of JNK cascade	GO:046330	10.0	IL1B, TLR4, NOD2, TNF, CCL21, TLR9
31	response to radiation	GO:009314	10.0	MMP9, CCL11, ANGPT2, IL18, TNFSF11, CXCL12
32	leukocyte cell-cell adhesion	GO:007159	10.0	TNIP1, ICAM1, CCL5, CD40LG, VCAM1, SELE
33	interferon-gamma-mediated signaling pathway	GO:060333	9.9	HLA-B, VCAM1, CIITA, IFNG, ICAM1, HLA-C
34	chemokine-mediated signaling pathway	GO:070098	9.9	CCR2, CCR4, CXCL12, CCL5, CCR5, CCL2
35	anti-apoptosis	GO:006916	9.8	NFKB1, NFKBIA, NGF, NGFR, IL2, CCL2
36	positive regulation of angiogenesis	GO:045766	9.8	MMP9, VEGFA, CHRNA7, CCL5, FGF1, FGF2
37	chemotaxis	GO:006935	9.8	CCL27, CCL5, CXCL1, CXCL10, CXCL12, CCL3
38	response to ethanol	GO:045471	9.7	ICAM1, IL4, TLR4, TNFRSF1A, TRH, CCL2
39	response to hypoxia	GO:001666	9.4	VCAM1, ANGPT2, MMP9, IL18, CXCL12, TLR4
40	cellular response to tumor necrosis factor	GO:071356	9.3	CCL5, CCL2, IL8, IL18, RELA, ICAM1
41	cellular response to lipopolysaccharide	GO:071222	9.2	IL12B, TNFRSF1B, IL10, IL8, ICAM1, CCL2
42	cellular response to interleukin-1	GO:071347	9.2	ICAM1, CCL5, CCL3, CCL2, IL8, IL17A
43	cytokine-mediated signaling pathway	GO:019221	9.1	HLA-A, HLA-DQA1, HLA-DRB1, CCR2, IL6, HLA-B
44	response to drug	GO:042493	9.1	MMP9, NGF, LTA, ABCC1, PPARG, TNFRSF11B
45	virus-host interaction	GO:019048	9.0	HLA-C, TP53, TNFRSF1A, MICB, VCAM1, RELA
46	angiogenesis	GO:001525	8.9	JAM3, ANGPT2, TNFSF12, EGF, TNFRSF12A, ERAP1
47	inflammatory response	GO:006954	8.7	IL17D, TNFRSF1A, TNFRSF1B, TNIP1, CRP, NGF
48	signal transduction	GO:007165	8.6	LPXN, EGF, S100A9, FGF1, FGF2, IL13
49	immune response	GO:006955	8.0	KIR2DL1, KIR2DL3, KIR3DL1, KIR2DS2, KIR2DS1, BPI
50	positive regulation of transcription from RNA polymerase II promoter	GO:045944	8.0	TLR9, TNF, TP53, IFNG, IL6, TLR4

Molecular functions related to psoriatic arthritis according to GeneDecks:

(show all 9)

id	Name	GO ID	Score	Top Affiliating Genes
1	tumor necrosis factor receptor binding	GO:005164	10.5	LTA, TNFSF12, TNFSF11, TNF, ERAP1, CD40LG
2	interleukin-1 receptor binding	GO:005149	10.4	IL1A, IL1B, IL1RN, TLR9
3	transmembrane signaling receptor activity	GO:004888	9.8	TLR4, TLR2, NGFR, ICAM1, IL1R1, CD79A
4	receptor binding	GO:005102	9.7	LTA, CXCL1, CXCL10, CXCL12, SLC9A3R1, TNFSF12
5	chemokine activity	GO:008009	9.5	CXCL13, IL8, CCL4, CCL27, CCL22, CCL2
6	heparin binding	GO:008201	9.2	CXCL13, COMP, CCL5, CCL2, APOH, FGF2
7	cytokine activity	GO:005125	8.6	TNFRSF11B, TNFSF11, TNFSF12, LTA, CSF3, TNF
8	growth factor activity	GO:008083	8.5	IL6, NGF, EGF, CXCL1, CXCL12, CSF3
9	protein binding	GO:005515	4.7	TNFRSF1A, TNFRSF1B, TNFSF12, TNIP1, PTPN22, SPPL2A